Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells

Conclusion Derivative10 is an novel antitumor agent with potential for further clinical applications to treat gastric cancer.Graphical abstract
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conditions:   Stomach Neoplasms;   Cancer Survivors Interventions:   Behavioral: The intervention group;   Other: Usual care Sponsors:   The Hong Kong Polytechnic University;   Wuhan Union Hospital, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
This study focused on S-1 adherence by evaluating real-world adherence to S-1 and investigating factors related to decreased S-1 adherence. This study included cases treated between August 1, 2014 and October 12, 2016 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. The S-1 adherence rate per cycle was defined as the number of times a patient took S-1/28. In this study, adherence to S-1 was assessed through pill counts and by asking the patient about the reason for non-adherence at a pharmaceutical outpatient clinic. Univariate and multivariate analyses were performed to investigate factors ...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSION: Thus, NR2F1-AS1 was verified to regulate GC cell progression by sponging miR-493-5p to upregulate MAP3K2 expression.PMID:34335755 | PMC:PMC8294992 | DOI:10.1155/2021/3881932
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: GC patients are often accompanied by changes in TMB, and its expression level is closely related to the degree of pathological differentiation, which is an independent factor affecting the prognosis of GC patients. High TMB value can evaluate the prognosis and provide a reference for the formulation of clinical treatment plans for GC patients.PMID:34335754 | PMC:PMC8321718 | DOI:10.1155/2021/3374939
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: miR-193a prominently decreased the proliferation, invasion, and activation of the PI3K/Akt signaling pathway and the abilities of epithelial-to-mesenchymal transition in gastric cancer cells. The newly identified miR-193a/PSEN1 axis provides novel insight into the pathogenesis of gastric cancer.PMID:34335753 | PMC:PMC8298175 | DOI:10.1155/2021/2804478
Source: Journal of Oncology - Category: Cancer & Oncology Authors: Source Type: research
The expression level of AURKA gene in 13 common cancers increased significantly compared to normal. The level of AURKA was significantly associated with resistance to SB 505124, NU-7441, and irinotecan drugs (p 1,p 
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
In conclusion, determination of SWI/SNF status could be suggested in routine diagnostics in genomically stable tumors to identify patients who might benefit from new therapeutic options.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Oncogene, Published online: 02 August 2021; doi:10.1038/s41388-021-01988-yAnoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBPβ-mediated PDGFB autocrine and paracrine signaling
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: The overall knowledge level of Saudi undergraduate students about H. pylori infection was low. Thus, health awareness interventions through educational programs are recommended for improving their knowledge about H. pylori infection and its prevention.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Investigational New Drugs